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Abstract: This study was carried out to
investigate clinical effects of treatment with
the supplementation of L-carnitine in cases
with dilated cardiomyopathy.
B Mode, M-Mode, and continuous Doppler
echocardiograms were applied with standard
techniques in totally 28 patients assessed
before treatment with L-carnitine and at the
1st , 5th , 10th , 30th , and 60th days of the
treatment.
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Faculty of Medicine, Fırat University,
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The diameter of the left ventricular endsystolic and end-diastolic have decreased with
L-carnitine treatment (p<0.05). While an
increase was observed in the interventricular
septum motion (p<0.0001); decrease was

Introduction
Treatment of the patients with dilated
cardiomyopathy still is one of the major problems in
cardiology. Available drugs are not able to affect longterm prognosis. Although the drugs used commonly
affect some of the clinical and physiopathological
features, they can not affect the conditions supporting
the pump-function of the myocardium (1, 2).
In recent studies, a decrease has been determined in
the carnitine concentration in the cardiac tissue of the
patients with dilated cardiomyopathy, when compared
with the normal ones. The heart has very high
concentration of carnitine and is highly dependent upon
fatty acid oxidation as a source of energy. In addition to
its key function as a transporter of long-chain fatty acids
across the inner mitochondrial membrane, carnitine plays
an important role in trapping toxic long-chain acyl CoA
metabolites which may accumulate in ischaemia and leads
to sarcolemmal membrane damage. Almost all of the
carnitine needed for myocardium is provided from
extracardiac tissues (3-9). Therefore, we have planned to
search the effects of carnitine on systolic and diastolic
functions of the left ventricle by adding L-carnitine to the

observed in the left ventricular end-systolic
and end-diastolic volumes (p<0.05), and an
increase was also observed in the ejection
fraction, myocardial fractional shortening,
and velocity of circumferential fiber
shortening (p<0.05). No significant change
occurred at the diastolic function of the left
ventricle.
As a conclusion, supplementation of Lcarnitine to the conventional therapy, dilated
cardiomyopathy treatment can give
successful clinical result in refractory cases.
Key
Words:
L-Carnitine,
Dilated
Cardiomypopathy, Doppler Echocardiography

treatment of the patients with dilated cardiomyopathy
and having conventional therapy.
Materials and Methods
Totally 28 patients (7 women and 21 men), who
clinically and echocardiographically diagnosed with dilated
cardiomyopathy (average age was 62±10 years and agerange was 39-82 years) were selected as subjects of the
study.
At first, the purpose and the applications of the study
were explained to all patients. Oral and written
permission of all patients were taken. Detailed history
was taken from each patient. After the physical
examination, required blood and urine assays were done.
New York Heart association functional capacity of
patients were between III and IV.
All of the cases who were treated with conventional
heart failure therapy have taken digitalis, diuretic, ACE
inhibitor, calcium antagonist, and antiarrhythmic drugs
and had no improvement for last three months.
After

the

patients’-subjected

to

the

study-
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Table.

Some parameters before and after L-carnitine treatment

Basal

1st.day

5th.day

10th.day

30th.day

60th.day

P

LVDD

75.21±9.38

74.90±9.62

73.57±8.56

73.20±7.61*

LVSD

61.03±9.56

61.43±9.56

58.97±7.81

59.97±6.87

72.00±8.69*

73.06±6.17

<0.05

59.97±6.87

57.35±7.54*

IVSM

4.78±1.73

5.80±2.19

5.50±2.22

<0.05

5.17±2.17

5.82±1.59

6.65±1.62*

<0.0001

EDV

465.34±164.84 462.44±168.95

433.22±144.87

428.24±124.65

424.13±163.60*

421.07±106.91*

<0.05

ESV

252.58±103.57 260.92±117.39

228.73±153.77

222.12±75.02*

220.90±94.43*

207.32±82.76*

<0.005

EF

44.99±7.13

46.57±7.90

48.07±8.35

48.04±6.29

49.98±12.10*

51.48±8.70*

<0.05

FS

18.23±3.53

19.65±4.82

19.88±4.46

19.69±3.42

21.21±6.38*

21.62±4.61*

<0.05

Vcf

0.81±0.20

0.84±0.24

0.90±0.32

0.88±0.17

0.92±0.23*

0.92±0.21*

<0.05

MVM

0.32±0.16

0.41±0.25

0.39±0.24

0.35±0.15

0.30±0.10

0.36±0.16

>0.05

EVM

0.20±0.10

0.24±0.10

0.28±0.32

0.25±0.16

0.22±0.11

0.25±0.11

>0.05

EVP

1.00±0.36

0.98±0.31

0.95±0.28

1.03±0.32

1.02±0.33

1.05±0.29

>0.05

AVM

0.15±0.12

0.23±0.22

0.16±0.12

0.13±0.05

0.14±0.11

0.16±0.08

>0.05

AVP

0.69±0.20

0.76±0.26

0.72±0.27

0.80±0.21

0.73±0.12

0.67±0.13

>0.05

AoVM

0.27±0.08

0.28±0.08

0.30±0.10

0.31±0.09

0.30±0.08

0.28±0.07

>0.05

AoVP

1.23±0.33

1.15±0.25

1.19±0.32

1.18±0.36

1.10±0.23

1.10±0.20

>0.05

LVDD: left ventricular end-diastolic diameter (mm), LVSD: left ventricular end-systolic diameter (mm), IVSM: interventricular septum motion (mm),
EDV: End-Diastolic Volume (ml), ESV: End-Systolic Volume (ml), EF: Ejection Fraction (%), FS: Fractional Shortening (%), Vcf: Mean circular
shortening velocity (Circ/sec), MVM: total mitral flow (m/sn), EVM: The mean flow velocity of the early diastolic filling (m/sn), EVP: The peak flow
velocity of early diastolic filling (m/sn), AVM: The mean flow velocity of the late diastolic filling (m/sn), AVP: The peak flow velocity of the late diastolic
filling (m/sn), AoVM: Aortic mean flow velocity (m/sn), AoVP: Aortic peak flow velocity (m/sn). p: Variance analysis, P Value, (*): Statistically significant
ones according to Tukey’s HSD.

haemodynamic evaluations have done with L-Carnitine
ampuls (Santa Farma-1 g) which were given
intravenously twice a day, After the 10th day, L- carnitine
pills (Santa Farma-1 g) were given per oral three times a
day with 8 hours intervals for fifty days.

obtained from the aortic valve by using standard
techniques. All measurements were done at least in 6
cardiac cycles and mean values were taken. The records
were taken at the same time with electrocardiography
and phonocardiography.

Haemodynamic evaluations were done after the
patients were in resting condition at the
echocardiography lab for an hour. Two dimensional Mmode and continuous Doppler echocardiograms were
applied with standard techniques. The echocardiograph
used was Sonolayer -SSH-60 Toshiba model, and videorecords were taken with Toshiba-V 73 D model. Toshiba
PSD-25RN tranducer was used in the study, and Toshiba
Line scan Recorder LSR 20B in the records. The speed of
the record was adjusted as 50 mm/sec. All of the patients
were examined from the parasternal and apical. The
criteria suggested by American Echocardiography society
were used in M-Mode echocardiograpic measurements.
The record of the transmitral blood velocity and
continuous Doppler cursor were placed in the area where
mitral valve is opened. Systolic blood velocity curve was

The left ventricular end-diastolic diameters (LVDD),
the left ventricular end-systolic diameters (LVSD), the left
ventricular diastolic posterior wall thickness (LVDPWT)
and its motion (LVDPWM), interventricular septum
thickness (IVST) and its motion (IVSM), the left atrium
diameter (LAD), the right ventricular end diastolic
diameter (RVEDD), aortic root (AR) and valve motion
(AM) and the E-IVS distance were measured.
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Having studied the diastolic functions of the left
ventricular; total mitral flow (MVM), the mean and peak
flow velocity of the early diastolic filling (EVM- EVP), the
mean and peak flow velocity of the late diastolic filling
(AVM, AVP), peak velocity rate of the early diastolic on
that of the late one (E/A) have been studied.
Just about to study the systolic functions of the left
ventricle were aortic peak flow velocity (AoVP), aortic
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mean flow velocity (AoVM). the left ventricular enddiastolic volume (EDV), the left ventricular end-systolic
volume (ESV), stroke volume (SV), cardiac output (CO),
ejection fraction (EF), fractional shortening (FS) and the
mean circular fractional shortening acceleration of the left
ventricle (Vcf) were calculated from standard formulas
(9-11).
All of these parameters were measured before the
patient has taken medicine and measured again on the 1st ,
5th , 10th , 30th and 60th day after taking medicine. For the
first ten days, carnitine ampul 12 mg was given as
intravenously to the patients twice a day in the morning
and evening. For later days, carnitine tablets 1 mg (totally
3 g/day) were given per oral three times a day.
One-way variance analysis (ANOVA) was used in the
repeated measurements to compare the first result with
those on the 1st , 5th , 10th , 30th and 60th days after taking
medicine. When a considerable difference was present
between the means values and ANOVA, Tukey’s HSD test
was applied. Group findings were identified as means
values±standard deviation. P<0.05 was taken as the
statistical significancy.
Results
Some clinical characteristics of the study and of the
control group were shown in the table.
While the LVDD was 75.21±9.38 mm at the
beginning, it decreased to 74.90±9.62 mm on the 1st
day, 73.57±8.56 mm on the 5th day, 73.20±7.61 mm on
the 10th day, 72.00±8.69 mm on the 30th day,
73.06±6.17 mm on the 60th day (p<0.05). According to
Tukey’s HSD, the decrease between the basal value and
the measurements on the 10th , 30th and 60th days were
significant (p<0.05).
While the basal value of LVSD was 61.03±9.56 mm,
it decreased to 61.43±9.56 mm on the 1st day
58.97±7.81 mm on the 5th day, 59.97±6.87 mm on the
10th day, 57.94±11.77 mm on the 30th day, and
57.35±7.54 mm on the 60th day after the treatment
(p<0.05). According to Tukey’s HSD, there was an
important difference between the basal value and on the
30th day value (p<0.05), between the basal value and on
the 60th day value (p<0.05), between on the 1st day value
and that on the 60th day (p<0.05).
While the IVSM before the treatment was 4.78±1.73
mm, it was 5.50±2.22 mm on the 1st day, 5.80±2.19
mm on the 5th day, 5.17±2.17 mm on the 10th day,
5.82±1.59 mm on the 30th day, and 6.65±1.62 mm on
the 60th day (p<0.0001). According to Tukey’s HSD, the

difference between the basal and the 60th day value was
statistically significant (p<0.0001).
There was no statistical significance among the
posterior-wall thickness of the left ventricular enddiastolic, posterior-wall motion of the left ventricular,
right ventricular diastolic diameter, and interventricular
septum thickness before and after the treatment
(p>0.05).
There was no statistical significance between the pre
and post L-Carnitine treatment values of the MVM, EVM,
EVP, AVM, and AVP (p>0.05) and the AoVM and AoVP
(p>0.05).
EDV was 465.34±164.84 ml before the treatment
and it was found as 462.44±168.95 ml on the 1st day,
433.22±144.87 ml on the 5th day, 428.24±124.65 ml
on the 10th day, 424.13±163.60 ml on the 30th day, and
421.07±106.91 ml on the 60th day after the treatment.
According to Variance analysis, the decrease in the EDV
was important at p<0.05 level. According to Tukey’s
HSD, the decrease between the basal value and the 30th
day value (p<0.05), between the basal value and the 60th
day value (p<0.05), and between the 1st day value and
the 30th day value (p<0.05), and between the 1st day
value and the 60th day value (p<0.05) were significant.
The basal value of the ESV was 252.58±103.57 ml,
and it was found as 260.92±117.39 ml on the 1st day,
228.73±153.77 ml on the 5th day, 222.12±75.02 ml on
the 10th day, 220.90±94.43 ml on the 30th day, and
207.32±82.76 ml on the 60th day. These values were
significant at p<0.005 level according to the variance
analysis. According to Tukey’s HSD, there was significant
difference between the basal value and the 10th day value
(p<0.005), between the basal value and the 30th day
value (p<0.005), between the basal value and the 60th
day value (p<0.005), and between the 1st day value and
the 30th day value (p<0.005), between the 1st day value
and the 60th day value (p<0.005).
EF before the treatment was 44.99±7.13 %, and
46.57±7.90 % on the 1st day, 48.07±8.35 % on the 5th
day, 48.04±6.29% on the 10th day, 49.98±12.10% on
the 30th day, and 51.48±8.70% on the 60th day. The
increase in EF was significant at p<0.05 level according to
variance analysis. According to Tukey’s HSD, there was a
significance between the basal value and the 30th day
value (p<0.05) and between the basal value and the 60th
day value (p<0.05).
FS prior to the treatment was 18.23±3.53% and was
19.65±4.48% on the 1st day, 19.88±4.46% on the 5th
day, 19.69±3.42% on the 10th day, 21.21±6.38% on
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the 30th day, and 21.62±4.61% on the 60th day. Increase
in FS was found significant (p<0.05). Tukey’s HSD was
significant between the basal values and the 30th and 60th
day values (p<0.05).
Vcf was found 0.81±0.20 circ/sec at the beginning
and 0.84±0.24 circ/sec on the 1st day, 0.85±0.32 circ/sec
on the 5th day, 0.88±0.17 circ/sec on the 10th day,
0.90±0.23 circ/sec on the 30th day, and 0.92±0.21
circ/sec on the 60th day after the treatment. There was a
significance at p<0.05 level according to variance
analysis. Increase in Vcf was significant between the basal
values and the 30th and 60th day values (p<0.05)
according to Tukey’s HSD.

fatty acids as substrates. Muscle and cardiac tissues need
enough carnitine concentrations, so they can do their
normal functions, but muscle and cardiac tissues are not
capable of synthesizing carnitine. Both are dependable to
adequate carnitine concentration (16).

Significant change could not be found between the
values of the stroke volume and cardiac output before
and after L-carnitine treatment (p>0.05).

The lack of plasma and myocardial carnitine causes
dilated cardiomyopathy has been shown in human and
animal models. When L-carnitine is given in high doses, it
has been discovered that the contractility of the left
ventricular is increased (5-7, 17, 18). Ghidini et al. (19)
have reported that improvement occurred in the
symptoms and findings of the patients with heart failure
by adding L-carnitine to their treatment. Our patients
with dilated cardiomyopathy told us that they felt better
after L-carnitine treatment. It was observed that their
exercise tolerance and life quality was also improved.

During L-carnitine application, one patient complained
from itching, two patients had headache, two patients
had distension in stomach, and two patients had
constipation. These conditions have not required to stop
the therapy.

In our study, significant decrease was observed at
LVDD and LVSD with L-carnitine treatment (p<0.05).
Tripp et al (20) also observed a decrease in the LVDD and
LVSD after they had applied L-carnitine treatment to the
patients with dilated cardiomyopathy for 2 months.

Discussion
L-carnitine is an essential co-factor having a major role
in the oxidation of the fatty acids which are the most
important energy producing pathway of the heart in
human and animal (3, 5, 8).
The role of L-carnitine in energy production from
fatty acid oxidation is obvious. L-carnitine takes part in
the shuttle mechanism whereby long-chain fatty acids are
transformed to acyl carnitine derivatives and transported
across the inner mitochondrial membrane. This is
impermeable to long-chain fatty acids and to their CoA
esters. Across the membrane, the acyl carnitine is
reconverted to carnitine and to acyl CoA, which
undergoes beta-oxidation. This interesting action of Lcarnitine is essential in heart free fatty acid metabolism.
L-carnitine has a role not only in energy production, but
also, has a role, in energy delivery from the
mitochondrium to the cytosol (6, 12, 13).
When long-chain acyl CoA metabolites accumulate,
they cause damage in sarcolemmal membranes.
Myocardial contractility decreases, and arrhythmia
occurs. L- carnitine ensures the long-chain acyl CoA,
which might cause deterioration in cell-membranes, and
hydroxy peroxides might lead to toxic effects and these
toxic effects could be eliminated with carnitine (6, 15).
Skeletal and cardiac muscles are largely dependable on
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Schiovani et al. (21) identified a specific increase in
the IVSM after they had applied L-carnitine treatment to
the patients with ischemic cardiomyopathy. After Lcarnitine treatment, we identified an increase in
interventricular septum motion. We think increase in the
interventricular septum motion is due to carnitine’s
improving the myocardial energy metabolism and
removing off the toxical long- chain acyl CoA metabolites
from the environment that may cause deterioration in
myocardial contractility and functions. That matter has
not been clarified specifically yet (6, 14, 15).
Carnitine has not made a considerable change in
parameters related to the left ventricular diastolic
functions. In the literature, we could not find any
information about the effect of L-carnitine on the left
ventricular diastolic functions.
In our study, EF increased after the carnitine
treatment. While EF before the treatment was
44.99±7.13%, it was 51.48±8.70% on the 60th day
(p<0.05). Waber et al (22) have identified that EF in
patients with cardiomyopathy has risen from 39% to
75% after one month treatment and to 69% after five
months therapy. Increase in EF can be explained with LCarnitine’s rising energy production and removing off the
long chained fatty acids that have toxic effects on
myocardium.
In our study, while the myocardial FS before the
treatment was 18.23±3.53%, it increased to
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21.62±4.61% on the 60th day (p<0.05). Chapoy et al.
(23) have mentioned that after 3 months therapy, the
myocardial FS in the patients with cardiomyopathy has
risen to 31% while it was 18% before the treatment.
Chapoy et al. (23) informed that a significant
improvement was present in Vcf of the patients with
dilated cardiomyopathy after L-carnitine treatment. [We

also have determined an improvement in Vcf values
(p<0.05).]
In conclusion, we suggest that L-carnitine can be
added to the treatment of the patients with dilated
cardiomyopathy in whom no more improvement has
occurred with standard treatment.
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